Clinical Trials Browser

NIH × Leukemia, Myeloid, Acute × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT00462605 2017-07-18

MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00012376 2013-01-09

Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer

Phase 1 Completed

35 enrolled

Classical hematologyOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, Blast Crisis, Hemoglobinuria, Paroxysmal, Thrombocytopenia, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Clinical Trials

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia

Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer